12:46 PM EDT, 10/21/2025 (MT Newswires) -- Pfizer's ( PFE ) Canadian operation Pfizer Canada said Tuesday that Health Canada has approved Abrysvo for use in people aged 18 to 59 years old at increased risk for respiratory syncytial virus-caused lower respiratory tract disease.

The new indication for the RSV stabilized prefusion F subunit bivalent vaccine is on top of the existing indications for people over 60 years old and infants from birth through six months of age through maternal immunization, the company said.

Price: 24.83, Change: +0.14, Percent Change: +0.56